Occult hepatitis B virus infection in patients with autoimmune liver diseases

Liver International

Volumn 29, Issue 3, 2009, Pages 434-442

  Georgiadou, Sarah P ^a   Zachou, Kalliopi ^a   Liaskos, Christos ^a,b   Gabeta, Stella ^a,b   Rigopoulou, Eirini I ^a   Dalekos, George N ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Autoimmune hepatitis; HBV DNA; Liver autoimmunity; Occult HBV infection; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARAFFIN; PREDNISOLONE; PROTHROMBIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD DONOR; BLOOD SAMPLING; CHILD; COMORBIDITY; CONTROLLED STUDY; DNA DETERMINATION; EMBEDDING; FEMALE; FOLLOW UP; GREECE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CHILD; CHOLANGITIS, SCLEROSING; DNA, VIRAL; FEMALE; GREECE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 59849117376     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01851.x     Document Type: Article

References (67)

1. World Health Organization; Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2004). WHO Web site, 2000. http://who.int/ inf-fs/en/fact204.html.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-3.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
4. Feitelson M, Lega L, Guo J, et al. Pathogenesis of post-transfusion viral hepatitis in children with beta-thalassemia. Hepatology 1994; 19: 558-68.
5. Mosley JW, Stevens CE, Aach RD, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995; 35: 5-12.
6. Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172-9.
7. The EASL Jury. EASL International consensus conference on hepatitis B, 13-14 September 2002, Geneva, Switzerland, Consensus statement. J Hepatol 2003; 38: 533-40.
8. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-57.
9. Chemin I, Trepo C. Clinical impact of occult HBV infection. J Clin Virol 2005; 34: 15-21.
10. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.
11. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse non-viral hepatic diseases. J Vir Hepat 2004; 11: 358-65.
12. Kazemi-Shirazi L, Peterman D, Muller C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol 2000; 33: 785-90.
13. Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: Clinical and virological significance. J Med Virol 1999; 58: 201-7.
14. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
15. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 54: 249-55.
16. Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-7.
17. Villa E, Grottola A, Buttafoco P, et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci 1995; 40: 8-13.
18. Hui CK, Lau E, Wu H, et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006; 35: 185-92.
19. Nirei K, Kaneko M, Moriyama M, Arakawa Y. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000; 43: 95-101.
20. Fabris P, Brown D, Tositti G, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004; 29: 160-6.
21. Fujiwara K, Tanaka Y, Orito E, et al. Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus related chronic liver disease. J Gastroenterol Hepatol 2004; 19: 1343-7.
22. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-5.
23. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
24. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
25. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313-8.
26. Hasegawa I, Orito E, Tanaka Y, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-a therapy for patients with chronic hepatitis C. Liver Int 2005; 25: 247-53.
27. Khattab E, Chemin I, Vuillermoz I, et al. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol 2005; 33: 150-7.
28. Giannini E, Ceppa P, Botta F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver 2003; 23: 12-8.
29. De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-36.
30. Marusawa H, Osaki Y, Kimura T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999; 45: 284-8.
31. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.
32. Iwai K, Tashima M, Itoh M, et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transpl 2000; 25: 105-8.
33. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
34. Lau GK, Wu PC, Liang R, Yuen ST, Lim WL. Persistence of hepatic hepatitis B virus after serological clearance of HBsAg with autologous peripheral stem cell transplantation. J Clin Pathol 1997; 50: 706-8.
35. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
36. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43 (Suppl. 1): S132-44.
37. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: An overview. Eur J Intern Med 2002; 13: 293-303.
38. Mackay R, Whittingham S, Fida S, et al. The peculiar autoimmunity of primary biliary cirrhosis. Immunol Rev 2000; 174: 226-37.
39. Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun Rev 2003; 2: 305-12.
40. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
41. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54: 528-32.
42. Zachou K, Liaskos C, Rigopoulou E, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 2006; 119: 203-12.
43. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2005; 42: 393-9.
44. Beuers U. Hepatic overlap syndromes. J Hepatol 2005; 42: 93-9.
45. Liaskos C, Rigopoulou E, Zachou K, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 2005; 24: 251-60.
46. Stefos A, Gatselis N, Zachou K, et al. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur J Intern Med 2008, in press.
47. Chemin I, Zoulim F, Merle P, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001; 34: 447-54.
48. Berasain C, Betes M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47: 429-35.
49. Chan HL, Tsang SW, Leung NW, et al. Occult HBV Infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol 2002; 97: 1211-5.
50. Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GB-GHGV on hepatocellular carcinoma in Europe: Results of a European concerted action. J Hepatol 1998; 29: 173-83.
51. Paterlini P, Driss F, Nalpas B, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low-endemic area. Hepatology 1993; 17: 20-9.
52. Enriquez J, Fuchs K, Martinez Cerezo FJ, Seminago R, Madoz P, Torras J. Demonstration of HCV-RNA and HBV-DNA in the serum of HBsAg negative patients with hepatocellular carcinoma. Eur J Epidemiol 1994; 10: 189-94.
53. Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-85.
54. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.
55. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus identification in HIV patients naïve for antiretroviral therapy. AIDS 2006; 20: 1253-60.
56. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
57. Penna A, Artini M, Cavalli A, et al. Long-lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
58. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 27: 591-607.
59. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-62.
60. Chen CJ. Time-dependent events in natural history of occult hepatitis B virus infection: The importance of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements. J Hepatol 2005; 42: 438-40.
61. Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
62. Calabrese LH, Zein ZZ, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9.
63. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.
64. Nobili V, Marcellini M, Devito R, Comparcola D, Vento S. Co-occurrence of chronic hepatitis B virus infection and autoimmune hepatitis in a young Senegalese girl. Eur J Gastroenterol Hepatol 2006; 18: 927-9.
65. Becheur H, Valla D, Loriot MA, Attar A, Bloch F, Petite JP. Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Dig Dis Sci 1998; 43: 2479-82.
66. Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989; 34: 1294-7.
67. Yeo W, Chan PKS, Chan HLY, Mo FKF, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001; 65: 473-7.